Top Biopharma Deal June 2021: iTeos – GSK for EOS-448 anti-TIGIT mAb for Solid Tumors

by | Jul 1, 2021

Top Biopharma Partnership by Upfront Cash and Equity

June 2021

iTeos development and commercialization deal with GSK for EOS-448

Announced: June 14, 2021

Total Deal Value: $2,075M

Upfront Cash: $625M

Upfront Equity: n/a

Option Payments: n/a

Milestones: $1,450M Dev. and Sales

Cost and Profit Split: 50% U.S.

Royalties: Tiered ex-U.S.

The Asset:

Phase II EOD-448 anti-TIGIT IgG1 mAb which binds to TIGIT and blocks its interaction with certain ligands, including CD155, CD112, and CD226 to activate an immune response from T cells and natural killer cells as part of the checkpoint pathway. IgG1 binds FcyR and triggers a pro-inflammatory cytokine release and activates antigen presenting cells and depletion of TIGIT+ Tregs and exhausted T cells.

Deal Structure:

Development and Commercial License

Partnership Features:

GSK is fully responsible for R&D costs, 50% of U.S. commercialization, and 100% of ex-U.S. commercialization.

The Details:

  • iTeos granted GSK exclusive, worldwide rights to develop and commercialize EOS-448 for solid tumors.
  • GSK will be fully responsible for global R&D costs, 50% of U.S. commercialization, and 100% of ex-U.S. commercialization costs.
  • iTeos Therapeutics will receive $625M up front and is eligible to receive up to $1.45B in milestone payments, a 50% cost and profit split in the U.S., and tiered royalties ex-U.S.

Last Month:

The Deal of the Month for May 2021 was also a TIGIT deal among Agenus and BMS for AGEN-1777. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting to schedule your personalized demo.

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.


Deal Profiles


Funding Rounds


Company Profiles


Product Profiles


Clinical Trials


Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

Get more done.

Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.

More Research by DealForma

Biotech and Pharma Deals in 2020

Biotech and Pharma Deals in 2020

Biotech and pharma deals in 2020 soared to an all-time high of 1,154 signed deals with $146.3 billion in total value, defying expectations that the global Covid-19 pandemic would hamper dealmaking. Global healthcare and life sciences R&D partnership activity was up 23 percent over 2019 and total deal values rose 31 percent from the previous year, driven in part by advances in technological and molecular understandings of disease pathways, and a drive toward targeted precision medicines.

read more
Biotech and Pharma M&A in 2020

Biotech and Pharma M&A in 2020

Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. We look at the extensive DealForma database to see how life sciences M&A activity shaped up in 2020 in more detail.

read more

You met on Zoom. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.